Literature DB >> 8368637

Early pulmonary physiologic abnormalities in beryllium disease.

G P Pappas1, L S Newman.   

Abstract

By using the beryllium-specific blood lymphocyte transformation test (BeLT) as a screening tool, it is possible to identify beryllium disease before clinical symptoms or radiographic abnormalities develop. Little is known about the early pulmonary physiologic abnormalities in granulomatous lung diseases. We compared two groups: (1) "surveillance-identified" early beryllium disease patients, detected using the blood BeLT in workplace screening projects (n = 21), and (2) "clinically identified" beryllium disease patients who presented with symptoms or radiographic abnormalities (n = 15). We measured spirometry, lung volumes, diffusing capacity for carbon monoxide, arterial blood gases, and maximal exercise capacity. Physiologic abnormalities occurred in 12 of 21 (57%) surveillance-identified patients. The most common derangement was a rise in the dead space to tidal volume ratio (VD/VT) during exercise, suggesting a pulmonary vascular abnormality. None of the surveillance-identified patients had pure restriction, and only one of 21 had an abnormal diffusing capacity. In comparison, 93% of clinically identified beryllium disease patients had one or more abnormalities, the most sensitive indicator being the exercise capacity. One-third had airflow limitation. Resting arterial blood gas analysis was abnormal in seven of 15 (47%), whereas diffusing capacity was low in only five of 15 (33%). Clinically identified patients performed less work, had more severe gas exchange abnormalities, and had higher VD/VT at maximal exercise than did surveillance-identified patients. We conclude that alterations in gas exchange and the pulmonary vascular bed occur early in beryllium disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8368637     DOI: 10.1164/ajrccm/148.3.661

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  11 in total

Review 1.  Chronic beryllium disease: an updated model interaction between innate and acquired immunity.

Authors:  Richard T Sawyer; Lisa A Maier
Journal:  Biometals       Date:  2010-10-28       Impact factor: 2.949

2.  Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease.

Authors:  Lisa A Maier; Briana Q Barkes; Margaret Mroz; Milton D Rossman; Juliana Barnard; May Gillespie; Allison Martin; Douglas G Mack; Lori Silveira; Richard T Sawyer; Lee S Newman; Andrew P Fontenot
Journal:  Respir Med       Date:  2012-09-11       Impact factor: 3.415

3.  Identification of multiple public TCR repertoires in chronic beryllium disease.

Authors:  Natalie A Bowerman; Michael T Falta; Douglas G Mack; Fabian Wehrmann; Frances Crawford; Margaret M Mroz; Lisa A Maier; John W Kappler; Andrew P Fontenot
Journal:  J Immunol       Date:  2014-04-09       Impact factor: 5.422

Review 4.  Significance of the blood beryllium lymphocyte proliferation test.

Authors:  L S Newman
Journal:  Environ Health Perspect       Date:  1996-10       Impact factor: 9.031

5.  Illness absences among beryllium sensitized workers.

Authors:  Janice P Watkins; Elizabeth D Ellis; David J Girardi; Donna L Cragle; Bonnie S Richter
Journal:  Am J Public Health       Date:  2014-09-11       Impact factor: 9.308

6.  Effect of inhaled corticosteroids on lung function in chronic beryllium disease.

Authors:  Margaret M Mroz; John H Ferguson; Anna V Faino; Annyce Mayer; Matthew Strand; Lisa A Maier
Journal:  Respir Med       Date:  2018-02-05       Impact factor: 3.415

7.  Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease.

Authors:  Margaret M Mroz; Lisa A Maier; Matthew Strand; Lori Silviera; Lee S Newman
Journal:  Am J Ind Med       Date:  2009-10       Impact factor: 2.214

8.  Rocky Flats Beryllium Health Surveillance.

Authors:  A W Stange; F J Furman; D E Hilmas
Journal:  Environ Health Perspect       Date:  1996-10       Impact factor: 9.031

Review 9.  The natural history of beryllium sensitization and chronic beryllium disease.

Authors:  L S Newman; J Lloyd; E Daniloff
Journal:  Environ Health Perspect       Date:  1996-10       Impact factor: 9.031

10.  Chronic beryllium disease: uncommon disease, less common diagnosis.

Authors:  D C Middleton
Journal:  Environ Health Perspect       Date:  1998-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.